PD‐L1 IHC expression has been extensively studied in NSCLC as potential predictive biomarker of response to anti‐PD1/PD‐L1 agents with contrasting results and is now adopted as selection criteria for Pembrolizumab in both 1st and 2nd line therapy (Herbst et al., 2016; Reck et al., 2016). The gene discussed is CD274; the disease is non-small cell lung carcinoma.